JP4684553B2 - 生理学的過程の調節およびこれに有用な薬剤 - Google Patents

生理学的過程の調節およびこれに有用な薬剤 Download PDF

Info

Publication number
JP4684553B2
JP4684553B2 JP2003530319A JP2003530319A JP4684553B2 JP 4684553 B2 JP4684553 B2 JP 4684553B2 JP 2003530319 A JP2003530319 A JP 2003530319A JP 2003530319 A JP2003530319 A JP 2003530319A JP 4684553 B2 JP4684553 B2 JP 4684553B2
Authority
JP
Japan
Prior art keywords
glutathione
brain
schizophrenia
mammal
metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003530319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508333A5 (enExample
JP2005508333A (ja
Inventor
アシュレイ アイ． ブッシュ
デイビッド エル． コポロフ
マイケル バーク
Original Assignee
ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23266273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4684553(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア filed Critical ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア
Publication of JP2005508333A publication Critical patent/JP2005508333A/ja
Publication of JP2005508333A5 publication Critical patent/JP2005508333A5/ja
Application granted granted Critical
Publication of JP4684553B2 publication Critical patent/JP4684553B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003530319A 2001-09-27 2002-09-26 生理学的過程の調節およびこれに有用な薬剤 Expired - Fee Related JP4684553B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32506101P 2001-09-27 2001-09-27
PCT/AU2002/001320 WO2003026684A1 (en) 2001-09-27 2002-09-26 Modulation of physiological processes and agents useful for same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010121582A Division JP2010215646A (ja) 2001-09-27 2010-05-27 生理学的過程の調節およびこれに有用な薬剤

Publications (3)

Publication Number Publication Date
JP2005508333A JP2005508333A (ja) 2005-03-31
JP2005508333A5 JP2005508333A5 (enExample) 2005-12-22
JP4684553B2 true JP4684553B2 (ja) 2011-05-18

Family

ID=23266273

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003530319A Expired - Fee Related JP4684553B2 (ja) 2001-09-27 2002-09-26 生理学的過程の調節およびこれに有用な薬剤
JP2010121582A Withdrawn JP2010215646A (ja) 2001-09-27 2010-05-27 生理学的過程の調節およびこれに有用な薬剤
JP2013149286A Expired - Fee Related JP5736421B2 (ja) 2001-09-27 2013-07-18 生理学的過程の調節およびこれに有用な薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010121582A Withdrawn JP2010215646A (ja) 2001-09-27 2010-05-27 生理学的過程の調節およびこれに有用な薬剤
JP2013149286A Expired - Fee Related JP5736421B2 (ja) 2001-09-27 2013-07-18 生理学的過程の調節およびこれに有用な薬剤

Country Status (10)

Country Link
US (3) US20050032708A1 (enExample)
EP (1) EP1438063B1 (enExample)
JP (3) JP4684553B2 (enExample)
AT (1) ATE468129T1 (enExample)
AU (1) AU2002333018B2 (enExample)
CA (1) CA2461703C (enExample)
DE (1) DE60236446D1 (enExample)
DK (1) DK1438063T3 (enExample)
ES (1) ES2346859T3 (enExample)
WO (1) WO2003026684A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057983A1 (en) * 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
WO2005017094A2 (en) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
AU2007308742A1 (en) * 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US7829709B1 (en) * 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
AU2010248758A1 (en) * 2009-05-15 2011-11-24 Intermune, Inc. Methods of treating HIV patients with anti-fibrotics
US20120041066A1 (en) * 2010-08-16 2012-02-16 Lombard Jay L Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20120270860A1 (en) * 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
JP6170166B2 (ja) 2012-10-30 2017-07-26 協和発酵バイオ株式会社 脳機能低下の予防または改善剤
JP2017534673A (ja) * 2014-09-15 2017-11-24 サウンド・ファーマシューティカルズ・インコーポレイテッド 精神病性障害を治療するための方法および組成物
EP3858344A4 (en) * 2018-09-28 2022-07-06 Keio University MARKERS FOR EVALUATION OF SENSITIVITY TO AN ANTI-CANCER COMBINATION AGENT
CN114786689A (zh) * 2019-11-18 2022-07-22 雀巢产品有限公司 用于在脑健康中使用的谷胱甘肽增强的组合物和方法
FR3119093B3 (fr) * 2021-01-27 2023-02-10 Nestle Sa Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5922765A (en) * 1996-01-18 1999-07-13 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US6329430B1 (en) * 1999-08-18 2001-12-11 Thomas Jefferson University Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione
US20020002146A1 (en) * 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB2368339B (en) * 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10112897B2 (en) 2013-11-08 2018-10-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10358414B2 (en) 2013-11-08 2019-07-23 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
US10961187B2 (en) 2013-11-08 2021-03-30 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds

Also Published As

Publication number Publication date
ES2346859T3 (es) 2010-10-21
WO2003026684A1 (en) 2003-04-03
EP1438063A4 (en) 2006-05-31
CA2461703C (en) 2011-04-05
JP2010215646A (ja) 2010-09-30
AU2002333018B2 (en) 2006-08-31
US20130065961A1 (en) 2013-03-14
US20180177839A1 (en) 2018-06-28
EP1438063B1 (en) 2010-05-19
CA2461703A1 (en) 2003-04-03
DK1438063T3 (da) 2010-08-30
JP2013234193A (ja) 2013-11-21
ATE468129T1 (de) 2010-06-15
US20050032708A1 (en) 2005-02-10
DE60236446D1 (de) 2010-07-01
JP5736421B2 (ja) 2015-06-17
JP2005508333A (ja) 2005-03-31
EP1438063A1 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
JP5736421B2 (ja) 生理学的過程の調節およびこれに有用な薬剤
Ebrahimi-Fakhari et al. Protein degradation pathways in Parkinson’s disease: curse or blessing
JP5542430B2 (ja) 神経変性疾患の治療
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN111788186A (zh) 治疗包括痴呆的神经紊乱的组合物和方法
CN104994912A (zh) 肽治疗剂及其使用方法
Weber et al. Thiazolidine-4-carboxylic acid, a physiologic sulfhydryl antioxidant with potential value in geriatric medicine
US20080107603A1 (en) Neuroprotectant methods, compositions, and screening methods thereof
US10022341B2 (en) Methods of preventing neurodegeneration of association cortex in a mammal
JP2012501301A (ja) ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
AU2019470001B2 (en) Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases
US20180117113A1 (en) Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity
JP4462382B1 (ja) Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
Chang et al. Transplantation of Pep-1-labeled mitochondria protection against a 6-OHDA-induced neurotoxicity in rats
TW383337B (en) Process of making (2S,5S)-5-fluoromethylornithine
Villar-Briones et al. Small molecular constituents of snake venoms
JP4734560B2 (ja) キノン体若しくはキノン体前駆体の毒性に起因する障害に対する予防治療剤
WO2023230560A1 (en) Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases
US20200016145A1 (en) Treatment of chronic traumatic encephalopathy
CN121102486A (zh) 含gls1抑制剂和ampk激活剂的药物组合物及其用途
Hariprasad Pharmacological Evaluation of Novel Drugs in Rat Models of Peripheral Neuropathy
Albano Regulation of the cystine/glutamate antiporter and its contribution to neuronal death
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
Suresh et al. The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees